TGTX — TG THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1001316 ·
Last close
$53.34
Market Cap
$8.17B
52W High
$59.30
52W Low
$26.76
ADV30
1,801,831
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 204,918,000 | 171,408,000 | 34,795,000 | 19,777,000 | 1,528,837,000 | 442,209,000 | 945,706,000 |
| Dec 2025 | 192,574,000 | 154,432,000 | 50,494,000 | 23,037,000 | 1,063,253,000 | 79,148,000 | 415,233,000 |
| Sep 2025 | 161,709,000 | 133,616,000 | 29,365,000 | 390,895,000 | 1,025,024,000 | 74,081,000 | 417,806,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,951,000
Investing CF
$16,869,000
Financing CF
$307,202,000
CapEx
$-240,000
Dividends Paid
$0
Buybacks
$-185,109,000
EPS Diluted TTM
$2.74
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,054,457,000
Inventory
$147,973,000
Receivables
$401,565,000
ST Investments
$69,673,000
EBIT TTM
$139,091,000
Pretax Income TTM
$101,599,000
Interest Exp TTM
$37,492,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$799,536,000
EBITDA
$136,451,008
Free Cash Flow
$59,134,500
Enterprise Value
$7,846,388,736
Total Cash
$552,248,000
Total Debt
$754,441,024
Shares Out
153,083,580
Trailing EPS
$2.74
Book Value
$4.11
ROE
100.3%
ROA
7.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 616,287,000 | 123,324,000 | 447,179,000 | 1,063,253,000 | 415,233,000 | 648,020,000 | -24,772,000 |
| Dec 2024 | 329,004,000 | 41,929,000 | 23,383,000 | 577,690,000 | 355,326,000 | 222,364,000 | -40,517,000 |
| Dec 2023 | 233,662,000 | 20,633,000 | 12,672,000 | 329,587,000 | 169,085,000 | 160,502,000 | -31,413,000 |
| Dec 2022 | 2,785,000 | -218,316,000 | -223,812,000 | 193,572,000 | 134,985,000 | 58,587,000 | -176,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$700,349,000
NetIncome TTM
$461,896,000
OpCashFlow TTM
—
Assets (Latest)
$1,528,837,000
Forward EPS
$2.96
Max Pain — expiry 2026-10-16
max pain strike: $55.00 · spot: $54.82 · call oi: 9,218 · put oi: 1,720
Expected Move to 2026-10-16:
±$3.00
(5.47%) —
implied range
$51.82 –
$57.82
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $8.58B | $60.74 | — |
| ABVX | Abivax S.A. | $7.77B | $89.05 | — |
| CYTK | CYTOKINETICS INC | $8.62B | $62.01 | — |
| AXSM | Axsome Therapeutics, Inc. | $8.91B | $170.08 | — |
| PTGX | Protagonist Therapeutics, Inc | $9.05B | $139.91 | — |
News headlines (Yahoo Finance, 1h cache)
How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story
2026-10-09 07:14 · Yahoo
TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow
2026-10-09 02:13 · Yahoo
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
2026-10-08 11:30 · Yahoo
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
2026-09-18 16:02 · Yahoo
TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
2026-09-16 20:02 · Yahoo
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 11:30 · Yahoo
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
2026-09-03 11:30 · Yahoo
IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point
2026-09-02 16:21 · Yahoo
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
2026-09-02 15:30 · Yahoo
TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis
2026-09-01 19:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.